16th Annual BIO CEO & Investor Conference
Dr. Paya will discuss Immune Design's clinical immuno-oncology programs, including those under the Specific Antigen approach, ID-LV305 and ID-G305, and the Endogenous Antigen Approach, G-100, as well as the company's discovery platforms, DCVexTM and GLAASTM.
About Immune Design
Immune Design is a clinical-stage biotechnology company employing leading-edge technologies that target in vivo dendritic cells to generate strong cytotoxic T cells (CTLs) for the treatment of cancer and other chronic diseases. The company's clinical programs are the product of its two synergistic discovery platforms: DCVexTM, a novel lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAASTM, a TLR4-agonist platform that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response. Immune Design has offices in
Julie Rathbun Rathbun Communicationsjulie@rathbuncomm.com 206.769.9219
Source: Immune Design